August was another busy month for HD research! Learnings from past trials, new approaches to huntingtin lowering, the start of INSIGHTT and PRECISE-HD, three packed days at HD2026, and the HDBuzz Prize: we’ve got you covered. 

The first participant has now been dosed in the Phase 3 PRECISE-HD trial of pridopidine for HD. The study will test whether the drug can slow disease progression in people most likely to benefit

⏱️5 min read | New research points to HTT1a, a toxic shortened form of huntingtin, as a key driver of disease and a promising therapeutic target in HD.